Sun Pharma reports strong Q2 FY26 revenue, EBITDA growth

Sun Pharmaceutical Industries reported Q2 FY26 sales of INR144,052 million, an 8.6% increase compared to Q2 FY25. The company’s EBITDA for the quarter rose 14.9% year-on-year to INR45,271 million, with the EBITDA margin percentage improving to 31.3% from 29.6%. Net profit after tax for Q2 FY26 reached INR31,180 million, up 2.6% over Q2 FY25, resulting in an EPS of INR13 per share.

The Global Innovative Medicines segment saw a 16.4% rise in sales to $313 million, with U.S. innovative medicine sales surpassing generics for the first time. The India formulation business recorded sales of INR47,348 million, an 11% growth over Q2 FY25, contributing 32.9% to consolidated sales. Sun Pharma holds an 8.3% market share in the Indian pharmaceutical market as of September 2025.

R&D investments for Q2 FY26 stood at INR7,827 million, representing 5.4% of sales, with innovative R&D accounting for 38% of the total spend. The company is preparing to launch UNLOXCYT in the U.S. in the second half of FY26 and plans to file ILUMYA psoriatic arthritis sBLA during the same period.